Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17861183 | 0.80 | ALDH1A1 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL17861188 | 0.79 | SLC6A2 (0.50) | IDO1TDO2CYP2D6KCNH2SLC6A4 | |
| SCHEMBL17861160 | 0.76 | MEN1 (0.38) | SLC6A4SLC6A3SLC6A2OPRM1LMNA | |
| SCHEMBL4911415 | 0.73 | CYP2D6 (0.64) | CHRNA7KAT2BCYP2D6KCNH2SLC6A4 | |
| SCHEMBL4912481 | 0.72 | LMNA (0.47) | IDO1TDO2KAT2BCYP2D6KCNH2 | |
| SCHEMBL17847835 | 0.72 | CES2 (0.39) | IDO1TDO2KAT2BKCNH2CYP3A4 | |
| SCHEMBL4902409 | 0.72 | CYP2D6 (0.54) | CHRNA7CYP2D6KCNH2SLC6A4SLC6A3 | |
| SCHEMBL4900306 | 0.71 | SIGMAR1 (0.44) | CYP2D6KCNH2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL17861303 | 0.71 | FNTA (0.31) | — | |
| SCHEMBL20694900 | 0.70 | SIGMAR1 (0.38) | IDO1TDO2KAT2BSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| EP-3233805-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | IDO1 1665/4885TDO2 2749/4885CHRNA7 66/4885 |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | IDO1 1724/4885TDO2 2755/4885CHRNA7 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.